➤ Get the DrugPatentWatch Daily Briefing

Get Daily Updates on Generic Entry, Litigation, Biosimilars, and more …

Serving leading biopharmaceutical companies globally:

McKesson
Mallinckrodt
Johnson and Johnson
Moodys
Merck
Harvard Business School

Last Updated: August 12, 2020

DrugPatentWatch Database Preview

Insulin aspart protamine recombinant; insulin aspart recombinant - Biologic Drug Details

➤ Get the DrugPatentWatch Daily Briefing
» See Plans and Pricing

« Back to Dashboard

Recent Clinical Trials for insulin aspart protamine recombinant; insulin aspart recombinant

Identify potential brand extensions & biosimilar entrants

SponsorPhase
Vancouver General HospitalPhase 4
SanofiPhase 4
Novo Nordisk A/SPhase 4

See all insulin aspart protamine recombinant; insulin aspart recombinant clinical trials

Recent Litigation for insulin aspart protamine recombinant; insulin aspart recombinant

Identify key patents and potential future biosimilar entrants

District Court Litigation
Case NameDate
NOVO NORDISK INC. v. SANDOZ INC.2020-06-04
SANOFI-AVENTIS U.S. LLC v. MYLAN N v.2017-10-24
Novo Nordisk Inc. v. Teva Pharmaceuticals USA, Inc.2017-03-03

See all insulin aspart protamine recombinant; insulin aspart recombinant litigation

PTAB Litigation
PetitionerDate
2014-01-23

See all insulin aspart protamine recombinant; insulin aspart recombinant litigation

Company Disclosures: US Patents for insulin aspart protamine recombinant; insulin aspart recombinant

These patents were extracted from company disclosures
Applicant Tradename Biologic Ingredient Dosage Form BLA Number Approval Date Patent No. Assignee Estimated Patent Expiration Status Orphan Source
Novo Nordisk Inc NOVOLOG MIX 50/50 insulin aspart protamine recombinant; insulin aspart recombinant INJECTABLE;SUBCUTANEOUS 021810 001 2017-11-21   Start Trial Novo Nordisk A/S (Basgsvaerd, DK) 2013-08-20 DISCN company
Novo Nordisk Inc NOVOLOG MIX 50/50 insulin aspart protamine recombinant; insulin aspart recombinant INJECTABLE;SUBCUTANEOUS 021810 001 2017-11-21   Start Trial Novo Nordisk A/S (Bagsvaerd, DK) 2014-04-08 DISCN company
Novo Nordisk Inc NOVOLOG MIX 50/50 insulin aspart protamine recombinant; insulin aspart recombinant INJECTABLE;SUBCUTANEOUS 021810 001 2017-11-21   Start Trial Novo Nordisk A/S (Bagsvaerd, DK) 2014-12-02 DISCN company
Novo Nordisk Inc NOVOLOG MIX 50/50 insulin aspart protamine recombinant; insulin aspart recombinant INJECTABLE;SUBCUTANEOUS 021810 001 2017-11-21   Start Trial Novo Nordisk A/S (Bagsvaerd, DK) 2013-06-21 DISCN company
Novo Nordisk Inc NOVOLOG MIX 50/50 insulin aspart protamine recombinant; insulin aspart recombinant INJECTABLE;SUBCUTANEOUS 021810 001 2017-11-21   Start Trial Novo Nordisk A/S (Bagsvaerd, DK) 2013-06-21 DISCN company
Novo Nordisk Inc NOVOLOG MIX 50/50 insulin aspart protamine recombinant; insulin aspart recombinant INJECTABLE;SUBCUTANEOUS 021810 001 2017-11-21   Start Trial Novo Nordisk A/S (Bagsvaerd, DK) 2016-06-20 DISCN company
Novo Nordisk Inc NOVOLOG MIX 50/50 insulin aspart protamine recombinant; insulin aspart recombinant INJECTABLE;SUBCUTANEOUS 021810 001 2017-11-21   Start Trial Novo Nordisk A/S (Bagsvaerd, DK) 2018-01-30 DISCN company
>Applicant >Tradename >Biologic Ingredient >Dosage Form >BLA >Number >Approval Date >Patent No. >Assignee >Estimated Patent Expiration >Status >Orphan >Source

Supplementary Protection Certificates for insulin aspart protamine recombinant; insulin aspart recombinant

Supplementary Protection Certificate SPC Country SPC Expiration SPC Description
05C/006 Belgium   Start Trial PRODUCT NAME: INSULIN GLULISINE; AUTHORISATION NUMBER AND DATE: EU/1/04/285/001 20040928
C0023 France   Start Trial PRODUCT NAME: INSULIN GLARGINE; NAT. REGISTRATION NO/DATE: EU/0/00/134/001 20000609; FIRST REGISTRATION: EU/1/00/134/001 20000609
2/2005 Austria   Start Trial PRODUCT NAME: INSULIN GLULISINE
2013000062 Germany   Start Trial PRODUCT NAME: KOMBINATION VON INSULIN DEGLUDEC UND INSULIN ASPART IN ALLEN DURCH DAS BASISPATENT GESCHUETZTEN FORMEN; REGISTRATION NO/DATE: EU/1/12/806/001 EU/1/12/806/004-005 EU/1/12/806/007-008 20130121
13/034 Ireland   Start Trial PRODUCT NAME: INSULIN DEGLUDEC; NAT REGISTRATION NO/DATE: EU/1/12/807-001, 004, 005, 007-009, 012, 013 015 20130121
/2017 Austria   Start Trial PRODUCT NAME: INSULIN GLARGIN UND LIXISENATID; REGISTRATION NO/DATE: EU/1/16/1157 (MITTEILUNG) 20170113
90036-0 Sweden   Start Trial PRODUCT NAME: KOMBINATION AV INSULIN DEGLUDEK OCH INSULIN ASPART; REG. NO/DATE: EU/1/12/806/001 20130121
>Supplementary Protection Certificate >SPC Country >SPC Expiration >SPC Description

Make Better Decisions: Try a trial or see plans & pricing

Serving leading biopharmaceutical companies globally:

Colorcon
Express Scripts
Merck
Harvard Business School
Johnson and Johnson
AstraZeneca

Drugs may be covered by multiple patents or regulatory protections. All trademarks and applicant names are the property of their respective owners or licensors. Although great care is taken in the proper and correct provision of this service, thinkBiotech LLC does not accept any responsibility for possible consequences of errors or omissions in the provided data. The data presented herein is for information purposes only. There is no warranty that the data contained herein is error free. thinkBiotech performs no independent verification of facts as provided by public sources nor are attempts made to provide legal or investing advice. Any reliance on data provided herein is done solely at the discretion of the user. Users of this service are advised to seek professional advice and independent confirmation before considering acting on any of the provided information. thinkBiotech LLC reserves the right to amend, extend or withdraw any part or all of the offered service without notice.